Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Several risk factors for CV disease are also risk factors for cataract….
Read More »Education Targeting Eye Care Needed for Diabetes Patients
Many patients with diabetes do not obtain annual eye care….
Read More »Lucentis Okay in Diabetic Eye Disease
Long-term use of Lucentis (ranibizumab) looks safe….
Read More »Microaneurysm Turnover Predicts Retinopathy Progression
Automated analysis of microaneurysm (MA) turnover predicted the development of clinically significant macular edema (CSME) among patients with mild nonproliferative diabetic retinopathy (MNDR)….
Read More »Retinopathy Improved with Ranibizumab
Researchers found that ranibizumab (Lucentis) may slow the progression of diabetic retinopathy….
Read More »Diabetic Macular Edema Responds Best to Ranibizumab
Aggressive treatment with ranibizumab during year 3 may be more effective for diabetic macular edema (DME) than less-intensive treatment, according to 3-year outcomes from an ongoing randomized published clinical trial….
Read More »New Drug for Diabetes-Related Vision Loss Approved
Last week, the new drug Lucentis was approved to treat diabetic macular edema….
Read More »VEGF Trap-Eye Improves Vision in Diabetes Patients
Vascular Endothelial Growth Factor (VEGF) Trap-Eye provided a significant benefit to patients with diabetic macular edema in a phase II trial – and updated data now shows the initial improvements were sustained or increased a year later….
Read More »Changes in the Eye Can Predict Heart Disease for Diabetes Patients
Arterial narrowing in retina seen as independent risk factor with type 1 diabetes….
Read More »Anti-VEGF Drug Reverses Diabetic Vision Loss
Patients headed toward blindness because of diabetic macular edema showed substantial gains in visual acuity after two years of treatment with the angiogenesis inhibitor drug ranibizumab (Lucentis), its manufacturer said….
Read More »